Amylyx Pharmaceuticals, Inc. AMLX

29.49 (0.65) (2.16%) as of 25 Sep
Market cap
$3.8B
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '17
P/E ratio
— 0.00 20.51 0.00 0.00 0.00 —
P/S ratio
— 2.95 2.64 0.00 0.00 0.00 —
P/FCF ratio
— 0.00 94.26 0.00 0.00 0.00 —
P/Operating CF
— (4.37) 74.27 (42.35) (4.21) (4.21) —
P/B ratio
— 1.56 2.32 6.18 0.00 0.00 —
Price to Tangible BV
— 1.56 2.32 6.18 0.00 0.00 —
EV/Sales
— 0.94 1.67 0.00 0.00 0.00 —
EV/EBITDA
— 0.00 21.25 0.00 0.00 0.00 —
EV/Operating CF
— (0.49) 53.41 (9.78) (0.33) (0.33) —
EV/FCF
— (0.40) 59.61 (9.64) (0.32) (0.32) —
Quick Ratio
13.98 6.23 5.01 7.77 5.53 1.76 —
Current Ratio
14.27 6.67 5.66 8.20 6.03 1.86 —
Net Debt/EBITDA
2.00 0.55 (12.40) 1.71 1.16 0.29 —
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 10.10% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.27 —
Asset Turnover
0.00 0.25 0.84 0.09 0.00 0.09 —
Operating CF/Net income
0.85 0.56 0.24 0.91 0.85 0.87 —
Capex/Depreciation
0.03 4.06 0.14 1.61 (2.04) (151.00) —
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 —
ROE
(61.59%) (100.88%) 12.73% (209.43%) 80.71% 0.00% —
ROA
(55.00%) (84.87%) 10.84% (79.82%) (146.90%) (599.55%) —
ROIC
0.00% 0.00% 39.07% 0.00% 0.00% 0.00% —
Return on Tangible Assets
(48.04%) (186.28%) 12.79% (58.67%) (99.89%) (654.08%) —
Average Days of Receivables
0.00 1.87 38.39 251.31 0.00 0.00 —
Research and Development Expense of Revenue
0.00% 119.13% 33.66% 420.38% 15,452.63% 3,783.69% —
Selling, General and Administrative Expense of Revenue
0.00% 130.86% 49.47% 571.88% 13,660.70% 2,317.08% —
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 37.81% 9.76% 97.68% 1,100.35% 37.38% —
Graham Net Nets
— 0.62 0.38 0.16 0.74 0.74 —
Graham Number
— 0.00 10.29 0.00 83.03 0.00 —
Earnings Yield
— (117.46%) 4.88% (9.53%) (73.88%) (73.88%) —
Free Cash Flow Yield
— (79.20%) 1.06% (8.67%) (63.15%) (63.15%) —
Revenue per Share
0.00 1.28 5.66 0.38 0.04 0.11 —
Operating CF per Share
(1.30) (2.46) 0.18 (3.07) (11.36) (6.04) —
Capex per Share
0.00 (0.53) (0.02) (0.04) (0.05) (0.02) —
Free Cash Flow per Share
(1.31) (2.99) 0.16 (3.12) (11.41) (6.06) —
Cash per Share
3.35 2.59 5.52 5.93 14.59 2.12 —
Shareholders Equity per Share
3.23 2.42 6.45 5.82 13.39 0.88 —
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 —
Book value per Share
3.23 2.42 6.45 5.82 13.39 0.88 —
Free Cash Flow
(123.48) (204.01) 10.68 (182.40) (75.15) (36.85) —
Working Capital
300.98 161.03 382.62 335.52 87.56 6.31 —
Capital Expenditures
(0.14) (36.36) (1.24) (2.53) (0.35) (0.15) —
Net Current Asset Value
296.29 160.56 380.64 331.29 87.52 4.87 —
EV/EBIT
— 0.00 16.41 0.00 0.00 0.00 —
Capex to Sales
0.00 0.42 0.00 0.11 1.24 0.23 —
Net Profit Margin
0.00% (345.36%) 12.94% (892.38%) (30,852.98%) (6,504.62%) —
Price to Operating Income
— 0.00 25.94 0.00 0.00 0.00 —
Other line items
Depreciation/Fixed assets
(16.13) (9.32) (3.30) (0.60) 0.37 0.01 —
Cash ROIC
(19.87%) (49.41%) 1.15% (26.54%) (40.84%) (187.63%) —
Accounts Receivable Turnover
0.00 4.31 13.76 0.00 0.00 0.00 —
Accounts Payable Turnover
0.00 9.97 1.80 0.56 0.00 — —
Inventory Turnover
— 0.00 1.06 0.00 — — —
Average Days of Payables
0.00 8.61 316.51 763.05 0.00 0.00 —
Days of Inventory on Hand
— 0.00 549.82 1,191.34 — — —
Average Receivables
0.27 20.25 27.68 — — — —
Average Payables
3.23 12.50 14.16 5.31 3.99 — —
Average Inventory
— — 24.05 — — — —
Average Assets
263.14 355.54 454.45 248.53 59.86 7.05 —
Average Common Equity
235.01 299.10 387.02 94.72 (108.95) — —

Fold the line items

Columns are period end dates